



ASX ANNOUNCEMENT

6 February 2024

RESULTS OF ENTITLEMENT OFFER

Highlights:

- **Non-Renounceable Pro-Rata Entitlement Offer (partially underwritten) raises \$4 million (before costs).**
- **Valid applications under the Shortfall and Top-Up Facility to be honoured in full.**
- **\$0.9 million (of \$1 million underwriting) taken up by the Underwriter (C2 Ventures – jointly owned by Chairman, Niall Cairns & CEO, Craig Cooper).**
- **Total Capital Raising of \$8 million (\$4 million Institutional Placement and \$4 million Entitlement Offer) now complete.**
- **New shares and options under the Entitlement Offer will be issued 7 February 2024.**
- **Continued progress being made and liaisons with ASX underway as to the reinstatement of trading in the Company's shares.**

CARDIEX Limited (ASX: CDX) (**CARDIEX, the Company**) is pleased to advise the results of the non-renounceable pro-rata entitlement offer prospectus lodged with ASIC and ASX on 19 December 2023 (**Prospectus**) to raise \$4 million. Combined with the completion of the Institutional Placement, the Company has now raised a total of \$8 million (before costs).

The Entitlement Offer was well supported by eligible shareholders, who applied for approximately 21,239,707 shares 7,080,020 quoted options under the entitlements and a further 5,613,064 shares 1,871,082 quoted options under the Top-Up Facility, representing a total of 54% take-up of the Entitlement Offer.

In addition, \$917,766.16 has been raised via Shortfall to new investors, representing 23% of the Entitlement Offer. Any shares or quoted options applied for in excess of entitlements are applied for under the Shortfall Offer and are issued in accordance with the terms and the allocation policy described in section 3.4 of the Prospectus.

The Entitlement Offer was partially underwritten (\$1 million) by C2V pursuant to the Underwriting Agreement as announced via the Supplementary Prospectus lodged on 18 January 2024. Under the terms of the Underwriting Agreement C2V has invested \$934,012.45 and thus will be issued with 11,675,156 shares and 3,891,719 quoted options. This represents 23% of the Entitlement Offer.

Shares and options under the Entitlement Offer for the \$4 million raised will be issued on Wednesday, 7 February 2024. The Entitlement Offer shares will rank equally with existing ordinary shares on issue.

MST Financial acted as Lead Manager to the Placement and Entitlement Offer.

The Company is liaising with the ASX and working towards meeting the conditions for reinstatement of trading outlined in the ASX announcement of 2 January 2024. The Company will keep shareholders and the market informed as progress is made.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

Investor Relations – USA

Matt Selinger

Managing Director, Integrous Communications

mselinger@integcom.com

About CARDIEX

CARDIEX focuses on increasing longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. CARDIEX is listed on the Australian Stock Exchange ("CDX").